Osteonecrosis of Maxilla Secondary to Bisphosphonate Therapy: A Case Report

  • Trupti Kolur
  • Sanjiv C. Nair
  • Balasubramanya Kumar
Case Report


Bisphosphonate chemotherapy is commonly used in the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions. The introduction of bisphosphonate therapy has improved the quality of life in a vast majority of patients. However, since 2003 a growing number of reports have described necrotic bone lesions (bisphosphonate—associated Osteonecrosis of the jaw [BR-ONJ]) a bone lesion affecting maxillofacial bones in patients who have received high dosage chemotherapy with intravenous bisphosphonate therapy especially when the patient undergoes subsequent dental procedures.

Sequential removal of sequestra as required seems to be the current conservative approach, but if large-volume debridement becomes necessary, removal of the bone sequestrum with minimal epithelial manipulation associated with topical and systemic antibiotics seem to be the treatment modality of choice. In our case, surgical salvage was performed successfully for BR-ONJ. Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with BR-ONJ.


Osteonecrosis Maxilla Bisphosphonate 


  1. 1.
    Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144(10):753–61. Review. Erratum in: Ann Intern Med. 2006 145(3):235Google Scholar
  2. 2.
    Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–440CrossRefPubMedGoogle Scholar
  3. 3.
    Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575CrossRefPubMedGoogle Scholar
  4. 4.
    Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood RG et al (2005) Novel insights into actions of bisphosphonates on bone differences in interactions with hydroxyapatite. Bone Google Scholar
  5. 5.
    Vaananen K (2005) Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:959–971CrossRefPubMedGoogle Scholar
  6. 6.
    Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–1107CrossRefPubMedGoogle Scholar
  7. 7.
    Marx RE (2003) Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMedGoogle Scholar
  8. 8.
    Miglioratti CA (2003) Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254CrossRefGoogle Scholar
  9. 9.
    Hellstein JW, Marek CL, Pharm BS (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw) is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689CrossRefPubMedGoogle Scholar
  10. 10.
    Hellstein J, Fielding C (2005) Bisphosphonate osteochemonecrosis clinical findings and treatment theories may relate to a possible analogy with “phossy” jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:189–190CrossRefGoogle Scholar
  11. 11.
    Ruggiero SL, Mehrotra B, Rosenberg T, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates a review of 63 cases. J Oral Maxillofac Surg 62:527–534CrossRefPubMedGoogle Scholar
  12. 12.
    Woo S, Hande K, Richardson PG (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102CrossRefPubMedGoogle Scholar
  13. 13.
    Santini D, Vincenzi B, Avvisati G et al (2002) Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 8:1080–1084PubMedGoogle Scholar
  14. 14.
    Carter GD, Goss AN (2005) Bisphosphonates and avascular necrosis of the jaw a possible association. Med J Aust 182:413–415PubMedGoogle Scholar
  15. 15.
    Landesberg R, Wilson T, Grbic JT (2006) Bisphosphonate associated osteonecrosis of the jaw: conclusion based on analysis of case series. Dent Today 25:52PubMedGoogle Scholar
  16. 16.
    Mignogna MD, Fedele S, Lo Russo L et al (2006) Case 2 osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 24:1475CrossRefPubMedGoogle Scholar
  17. 17.
    Soileau KM (2006) Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related malignancy. J Periodontal 77:738CrossRefGoogle Scholar
  18. 18.
    John JF, Rebecca PB (2007) Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 65:1321–1327CrossRefGoogle Scholar

Copyright information

© Association of Oral and Maxillofacial Surgeons of India 2011

Authors and Affiliations

  • Trupti Kolur
    • 1
  • Sanjiv C. Nair
    • 1
  • Balasubramanya Kumar
    • 1
  1. 1.Bhagwan Mahaveer Jain HospitalBangaloreKarnataka

Personalised recommendations